Wednesday

Keynote II: Bryant Lin offers hope as patient and physician

Dr. Lin offered insights into his experience as a patient with stage 4 lung cancer and how it has changed his outlook as a physician and encouraged greater understanding of the patient experience.

Promising Outcomes with SABR for Patients with RCC

Reports from FASTRACK and FASTRACK II on SABR for patients with renal cell carcinoma who cannot undergo surgical resection
By James B. Yu, MD, MHS, FASTRO, Dartmouth Hitchcock Medical Center

NRG GU-005: SBRT Shows Lower Bowel QOL Decline

Results of bowel and urinary quality of life outcomes for patients treated with SBRT vs. hypofractionated IMRT at two years.
By Daniel A. Hamstra, MD, PhD, FASTRO, Baylor College of Medicine

QOL Results from NRG-GU005

Results on all QOL domains at one year with the domains not included in the primary analysis, which were presented during the Plenary, presented at two years.
By Daniel A. Hamstra, MD, PhD, FASTRO, Baylor College of Medicine

Proton Therapy in H&N Cancers: Updates from ASTRO 2025

Three seminal studies presented at ASTRO 2025 in the management of head and neck cancer that help guide our understanding of the value of proton therapy in this patient population.
By James E. Bates, MD, Winship Cancer Institute, Emory University

ASTRO Business Meeting and Luncheon

The Business Meeting and Luncheon was held to discuss the past year of programs and events and to look ahead at what is to come. With the passing of the gavel, the meeting also marks the start of the new board year as Dr. Keole assumes his new role as ASTRO Chair and Dr. Vapiwala becomes President.